Use of High-Sensitivity Cardiac Troponin in Patients With Kidney Impairment
Peter J. Gallacher, Eve Miller‐Hodges, Anoop Shah, Atul Anand, Neeraj Dhaun, Nicholas L. Mills, High-STEACS Investigators, Nicholas L. Mills, Fiona E. Strachan, Christopher Tuck, Anoop Shah, Atul Anand, Tariq Farrar, Nynke Halbesma, James P. Blackmur, Andrew R. Chapman, Amy V. Ferry, Kuan Ken Lee, Dennis Sandeman, Philip D Adamson, Catherine L. Stables, Catalina A. Vallejos, Athanasios Tsanas, Lucy Marshall, Stacey Stewart, Takeshi Fujisawa, Mischa Hautvast, Jean McPherson, Lynn McKinlay, David E. Newby, Keith A.A. Fox, Colin Berry, Simon Walker, Christopher J. Weir, Alasdair Gray, Paul Collinson, Fred S Apple, Alan Reid, Anne Cruikshank, Iain Findlay, David McAllister, Donogh Maguire, Jack PM Andrews, Alastair J. Moss, Mohamed Anwar, John Hung, Jonathan Malo, Colin Fischbacher, Bernard Croal, Stephen J Leslie, Catriona Keerie, Richard Parker, Allan Walker, Ronnie Harkess, Tony Wackett, Roma A. Armstrong, Laura Stirling, Claire MacDonald, Imran Sadat, Frank Finlay, Heather Charles, Pamela Linksted, Stephen J. Young, Bill Alexander, Chris Duncan
Abstract
High-sensitivity cardiac troponin (hs-cTn) assays have improved the diagnosis of myocardial infarction in patients with healthy kidney function and are now widely used in clinical practice. 1 However, in patients with kidney impairment, long-term elevations in troponin levels are common, and interpretation can be more challenging. 2 As such, the effect of implementing hs-cTn testing on the diagnosis and outcomes of patients with kidney impairment is uncertain.